BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 23813885)

  • 1. Management of retinopathy of prematurity.
    Fleck BW
    Arch Dis Child Fetal Neonatal Ed; 2013 Sep; 98(5):F454-6. PubMed ID: 23813885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
    Erol N; Gürsoy H; Sahin A; Basmak H
    J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
    Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.
    Hartnett ME
    Clin Perinatol; 2014 Dec; 41(4):925-43. PubMed ID: 25459781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
    Kim J; Kim SJ; Chang YS; Park WS
    Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case report.
    Flavahan PW; Lavy TE; Wykes W
    Scott Med J; 2013 Aug; 58(3):130-2. PubMed ID: 23960050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
    Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
    Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future trends in treatment of severe retinopathy of prematurity.
    Wallace DK; Wu KY
    Clin Perinatol; 2013 Jun; 40(2):297-310. PubMed ID: 23719311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
    Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
    Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of neovascularization and expression shift of pro-/anti-angiogenic vascular endothelial growth factor isoforms after intravitreal bevacizumab injection in oxygen-induced-retinopathy mouse model.
    Shi X; Zhao M; Xie WK; Liang JH; Miao YF; DU W; Li XX
    Chin Med J (Engl); 2013 Jan; 126(2):345-52. PubMed ID: 23324288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinopathy of prematurity.
    Jordan CO
    Pediatr Clin North Am; 2014 Jun; 61(3):567-77. PubMed ID: 24852153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
    Kychenthal A; Dorta P
    Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity.
    Mititelu M; Chaudhary KM; Lieberman RM
    J Pediatr Ophthalmol Strabismus; 2012; 49(6):332-40. PubMed ID: 22938516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are we there yet? Bevacizumab therapy for retinopathy of prematurity.
    Darlow BA; Ells AL; Gilbert CE; Gole GA; Quinn GE
    Arch Dis Child Fetal Neonatal Ed; 2013 Mar; 98(2):F170-4. PubMed ID: 22209748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
    Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
    Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab.
    Ittiara S; Blair MP; Shapiro MJ; Lichtenstein SJ
    J AAPOS; 2013 Jun; 17(3):323-5. PubMed ID: 23607977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Retinopathy of prematurity - therapy. Part 2].
    Prepiaková Z; Tomčíková D; Kostolná B; Gerinec A
    Cesk Slov Oftalmol; 2014 Apr; 70(2):50-4. PubMed ID: 25030312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.
    Kong L; Bhatt AR; Demny AB; Coats DK; Li A; Rahman EZ; Smith OE; Steinkuller PG
    Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):956-61. PubMed ID: 25613938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity.
    Moran S; O'Keefe M; Hartnett C; Lanigan B; Murphy J; Donoghue V
    Acta Ophthalmol; 2014 Sep; 92(6):e496-7. PubMed ID: 24428792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.